Pfizer Inc.: Breakthroughs that change patients’ lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.
Location: United States
Employees: 51-200
Total raised: $1.35B
Founded date: 2002
Investors 2
| Date | Name | Website |
| - | Rho Ventur... | rhoventure... |
| - | Red Abbey ... | redabbey.c... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 29.03.2020 | - | $1.25B | - |
| 04.11.2010 | Grant | $1.5M | - |
| 07.01.2009 | - | $50M | - |
| 05.02.2007 | - | $50M | - |
Mentions in press and media 15
| Date | Title | Description |
| 10.12.2025 | 5 Things to Know The Fed meeting, pressure on Oracle, Target’s fashion-forward renovation and more in Morning Squawk | Fed funds futures are pricing in a nearly 90% chance of a quarter percentage point reduction to the central bank’s key interest rate. Eli Lilly said it will spend $6 billion building an Alabama manufacturing plant that will support producti... |
| 22.11.2024 | Amazon doubles down on Anthropic, positioning itself as a key player in the AI arms race | Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More The artificial intelligence arms race heated up Friday as Amazon announced an additional $4 billion investment in... |
| 29.03.2020 | Pfizer Completes $1.25 Billion Sustainability Bond | Biopharmaceutical giant Pfizer Inc. (NYSE: PFE) completed a $1.25 billion ten-year “sustainability” bond paying interest semi-annually of 2.625 percent and maturing April 1, 2030. This is the company’s first-ever sustainability bond. Procee... |
| 25.05.2018 | Pfizer, Merck Lead Strata Oncology’s $26M Series B Round | Share Share on Facebook Share on Twitter LinkedIn Email Reprints In what company leaders describe as a “huge step,” Ann Arbor, MI-based precision medicine startup Strata Oncology this week closed a $26 million Series B investment round led ... |
| 27.09.2017 | Pfizer Spin Off Lands $103M to Develop New Drugs for Undeserved Patient Populations | SpringWorks Therapeutics, a new Pfizer spin-off launched as a way to advance investigational drug therapies that may hold significant promise for underserved patients has raised $103 million in funding in Series A funding. The Series A roun... |
| 06.09.2011 | BARDA pledges GSK up to $94.5M to develop biothreat antibiotic | “We welcome this agreement with BARDA, which will support the development of GSK2251052 and important research into medical countermeasures for bioterrorism,” David Payne, head of antibacterial drug discovery at GSK said in a statement. “Su... |
| 06.09.2011 | GSK expands antibacterial rights; adds malaria, TB to Anacor R&D pact | British pharma GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina, started its partnership with Anacor in 2007 to develop anti-infectives against four targets. After a phase 1 trial, GSK last year exercised its o... |
| 04.11.2010 | Anacor Pharmaceuticals Receives $1.5M US Treasury Grant | Anacor Pharmaceuticals, a Palo Alto, CA-based biopharmaceutical company developing small molecule therapeutics derived from its boron chemistry platform, was awarded approximately $1.5m in grant funding from the United States Department of ... |
| 07.01.2009 | Anacor takes $50M to treat fungal infections | Anacor Pharmaceuticals, a Palo Alto, Calif. firm working on topical treatments for fungal infections in nails, just got a $50 million infusion in a fifth round of funding. This is pretty good news for a company that had to withdraw its IPO ... |
| 24.12.2008 | Drug developer Anacor cancels IPO plans | Biotech firm Anacor Pharmaceuticals has withdrawn its filing to go public after an arduous 16-month wait (unprecedented for health care enterprises, reports VentureWire). The Palo Alto, Calif.-based company says the market is not optimal to... |
Show more